In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Synthetic Biologics (SYN – Research Report), with a price target of $4.00. The company’s shares closed yesterday at $1.07.
McCarthy covers the Healthcare sector, focusing on stocks such as Adial Pharmaceuticals, Atossa Therapeutics, and Moleculin Biotech. According to TipRanks, McCarthy has an average return of -44.1% and an 8.84% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Synthetic Biologics with a $14.00 average price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $4.70 and a one-year low of $1.03. Currently, Synthetic Biologics has an average volume of 197.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
Read More on SYN:
- Synthetic Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
- Synthetic Biologics Announces Presentation at ESMO Congress 2022 Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck
- Synthetic Biologics Reports Second Quarter 2022 Operational Highlights and Financial Results
- Synthetic Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2022 Operational Highlights and Financial Results
